Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals

G Fabbri; I Mastrorosa; A Vergori; L Timelli; P Lorenzini; M Zaccarelli; S Cicalini; R Bellagamba; M M Plazzi; V Mazzotta; A Antinori; A Ammassari

doi:10.1111/hiv.12632

Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals

HIV Med. 2018 Jun 28. doi: 10.1111/hiv.12632. Online ahead of print.

Authors

G Fabbri¹, I Mastrorosa¹, A Vergori¹, L Timelli¹, P Lorenzini¹, M Zaccarelli¹, S Cicalini¹, R Bellagamba¹, M M Plazzi¹, V Mazzotta¹, A Antinori¹, A Ammassari¹

Affiliation

¹ Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.

PMID: 29953713
DOI: 10.1111/hiv.12632

Abstract

Objectives: Only a few studies have addressed liver stiffness dynamics after hepatitis C virus (HCV) treatment in patients with HIV/HCV coinfection. The aim was to evaluate the variation in liver stiffness and in serum liver fibrosis scores in HIV/HCV-coinfected patients before and after treatment with direct-acting antivirals (DAAs).

Methods: Liver stiffness measured using transient elastography as well as serum liver fibrosis scores [fibrosis-4 (FIB-4) score and the aspartate aminotransferase to platelet ratio index (APRI)] were evaluated before and at 6-12 months after DAA treatment. Variation in the outcome variables was evaluated using the Wilcoxon nonparametric test. Univariate analysis and multivariate regression models were used.

Results: A total of 78 HIV/HCV-coinfected subjects were included in the study. Median values of hepatic stiffness significantly decreased after DAA treatment compared with baseline [16.8 (interquartile range (IQR) 10.2-27.0) kPa at baseline vs. 9.4 (IQR 6.7-15.0) kPa after DAA treatment; P < 0.01). Further, a decrease in median FIB-4 score [2.8 (IQR 1.5-4.8) vs. 2.0 (IQR 1.3-3.2), respectively; P < 0.01] and APRI [0.9 (IQR 0.5-2.2) vs. 0.4 (IQR 0.2-0.7), respectively; P < 0.01] was found. In univariate analysis, liver stiffness decrease was associated with increasing age, 'other' HCV genotype (vs. G1), the presence of cirrhosis, higher pre-DAA liver stiffness, sofosbuvir-based regimens and longer DAA treatment (all P < 0.05). Multivariate regression confirmed the significance of the association only with higher baseline liver stiffness (P < 0.01). Greater FIB-4 and APRI reductions were associated with higher respective baseline values, while the presence of hepatic steatosis correlated with lower score reduction after DAA.

Conclusions: A reduction in liver stiffness and an improvement in fibrosis scores were observed in HIV/HCV-coinfected patients soon after DAA treatment. The clinical implications of these observations need to be evaluated in larger populations with longer follow-up.

Keywords: HIV; direct-acting antiretrovirals; hepatitis C; liver stiffness.